Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Securing the future of drug discovery for central nervous system disorders

Nature Reviews Drug Discovery volume 13, pages 871–872 (2014)Cite this article

Subjects

Innovative partnerships among researchers, patients, regulators, payors and industry are needed to reinvigorate drug discovery for central nervous system disorders. Here, we summarize plans of the Collegium Internationale Neuro-Psychopharmacologicum (CINP) to achieve this goal.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Riordan, H. & Cutler, N. The death of CNS drug development: overstatement or omen? J. Clin. Stud. 3, 12–15 (2011).

    Google Scholar 

  2. Zohar, J. et al. A proposal for an updated neuropsychopharmacological nomenclature. Eur. Neuropsychopharmacol. 24, 1005–1014 (2014).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge M. Loughlin, Z. Baxter and A. Grigg of Inspired Science who provided medical writing and editorial support.

Author information

Authors and Affiliations

  1. Innovation Fund Denmark, Østergade 26a, København K, Copenhagen, DK–1100, Denmark

    Peter Høngaard Andersen

  2. US Food and Drug Administration, Silver Spring, 20993, Maryland, USA

    Richard Moscicki

  3. Department of Psychiatry and Medical Research Council and the Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, CB2 2QQ, UK

    Barbara Sahakian

  4. McGill University, 3605 Mountain Street, Montreal, H3G 2M1, Quebec, Canada

    Rémi Quirion

  5. Duke University, and Dean of Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857.,

    Ranga Krishnan

  6. Deutsche Bank, 1 Great Winchester Street, London, EC2N 2EQ, UK

    Tim Race

  7. University of British Columbia, 430–5950 University Boulevard, Vancouver, V6T1Z3, Canada

    Anthony Phillips

Consortia

on behalf of the 2013 CINP Summit Group

  • Peter Høngaard Andersen
  • , Richard Moscicki
  • , Barbara Sahakian
  • , Rémi Quirion
  • , Ranga Krishnan
  • , Tim Race
  •  & Anthony Phillips

Corresponding author

Correspondence to Peter Høngaard Andersen.

Ethics declarations

Competing interests

The author declare no competing financial interests.

Supplementary information

Supplementary information S1 (box)

Attendees at 2013 CINP Summit (PDF 200 kb)

Related links

Related links

FURTHER INFORMATION

Report to the US President on propelling innovation in drug discovery, development and evaluation

Best Practice guidance for Pilot EMA HTA Parallel Scientific Advice procedures

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

on behalf of the 2013 CINP Summit Group. Securing the future of drug discovery for central nervous system disorders. Nat Rev Drug Discov 13, 871–872 (2014). https://doi.org/10.1038/nrd4489

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4489

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research